

Peer Review

Review of: "Long-Term Risk of Medication-Related Osteonecrosis of the Jaw (MRONJ) After Bisphosphonates and/or Denosumab in Metastatic Breast Cancer Patients"

Hany Akeel Al-hussaniy¹

1. University of Baghdad, Iraq

This commentary provides a clinically relevant and well-balanced appraisal of the long-term MRONJ risk in metastatic breast cancer patients receiving bisphosphonates and/or denosumab, and it appropriately highlights the value of Brunner et al.'s 20-year real-world dataset in clarifying cumulative risk over prolonged exposure. The authors demonstrate strong domain expertise by raising thoughtful methodological and interpretative questions, particularly regarding time-to-event definitions, sequencing effects, treatment duration, and survival confounding. Their focus on the heterogeneous sequential-therapy group is especially valuable and could stimulate further secondary analyses. However, the commentary could be strengthened by improving structural clarity and sharpening its key messages. Some sections are descriptive rather than analytical, and consolidating the critique into clearly labeled thematic subsections (e.g., time-to-MRONJ definition, sequential therapy heterogeneity, survival bias, temporal treatment era effects) would enhance readability. Additionally, incorporating a brief quantitative contextualization of absolute risk differences or cumulative incidence curves would make the discussion more data-driven. The manuscript could also benefit from a concise paragraph explicitly outlining clinical implications (e.g., de-escalation strategies, duration limits, risk stratification models) to translate the critique into practical guidance. Finally, while appropriately cautious, the commentary might briefly acknowledge the inherent limitations of retrospective datasets to maintain balance. Overall, this is a thoughtful and constructive contribution that would gain further impact through tighter organization, clearer prioritization of arguments, and more explicit clinical take-home points.

Declarations

Potential competing interests: No potential competing interests to declare.